Genmab pays $8B to buy Merus and its phase 3 bispecific that wowed analysts

Genmab has acquired Netherlands-based Merus for $8 billion, paying $97 per share, a 41% premium, to obtain petosemtamab, a late-stage bispecific antibody for recurrent or metastatic head and neck squamous cell carcinoma. This strategic acquisition, praised by analysts for petosemtamab's "best-in-disease profile" and 79% 12-month Phase 2 survival rate, accelerates Genmab's shift towards a wholly-owned pipeline, with projections for $1 billion in annual sales by 2029 and multi-billion-dollar potential thereafter, significantly bolstering its oncology portfolio.

Analysis

Genmab's acquisition of Merus for $8 billion, representing a significant 41% premium at $97 per share, is a decisive strategic move to accelerate its transition to a wholly-owned commercial pipeline. This transaction is centered on acquiring the late-stage bispecific antibody, petosemtamab, which has demonstrated a compelling 'best-in-disease profile' with a 79% 12-month survival rate in a Phase 2 trial for head and neck cancer. The deal builds on Genmab's recent M&A activity, including the $1.8 billion purchase of ProfoundBio, reinforcing a clear strategy to shift away from its legacy royalty-based model. Management has provided ambitious but specific guidance for petosemtamab, projecting a 2027 market launch, $1 billion in annual sales by 2029, and multi-billion-dollar revenue potential thereafter. This outlook is supported by analyst estimates, with William Blair forecasting peak sales of $3 billion to $4 billion in head and neck cancer alone. The acquisition is viewed favorably by the market, with analysts at Citi calling it a 'storybook conclusion' for Merus and highlighting the strong strategic fit with Genmab's expertise in antibody development, solidifying a pipeline with four potential wholly-owned drug launches by 2027.

Key Decisions for Investors

• For Genmab investors, this acquisition significantly enhances the long-term growth outlook by securing a high-potential, late-stage asset, but the primary focus should be on the Phase 3 trial readouts for petosemtamab expected next year, which will be the key catalyst to validate the $8 billion valuation.
• Merus shareholders are realizing immediate and substantial value through the 41% premium, which represents a highly favorable cash exit and a strong validation of the company's platform.
• Investors should weigh the significant execution risk, as the achievement of Genmab's ambitious sales targets is entirely contingent on successful Phase 3 outcomes, regulatory approvals, and effective commercialization in the competitive oncology landscape.